What's Happening?
Counsel Health, an artificial intelligence-native primary care company, has introduced a new weight management program. This program integrates obesity medications with on-demand physician consultations and AI-based monitoring. The company has partnered
with Eli Lilly to make this service accessible through LillyDirect, Eli Lilly's direct-to-consumer platform. The program allows Counsel members in 44 states to connect with board-certified physicians for questions regarding side effects, dosing, and treatment progress. Following a digital intake, Counsel physicians assess eligibility and develop personalized treatment plans, which can include prescribing weight loss medications such as Wegovy, Zepbound, and Foundayo. Counsel Health emphasizes that its AI-native care model aims to provide continuous access to high-quality medical care at a lower cost than traditional programs, offering both annual membership and pay-as-you-go options. The platform's AI solutions are available at no additional cost.
Why It's Important?
This initiative is significant as it addresses a critical gap in ongoing, personalized care for individuals using weight-loss medications, particularly GLP-1s. According to Counsel Health CEO and founder Muthu Alagappan, M.D., while weight-loss medications are increasingly available, the support systems for managing chronic conditions like obesity have not kept pace. Fragmented healthcare systems often make it difficult for patients to receive continuous support, leading to low adherence rates; only 32% of GLP-1 users remain on therapy after one year, dropping to 15% by the second year. By combining medical AI with physician-led care, Counsel Health aims to improve patient outcomes by providing constant access to medical guidance and proactive monitoring of progress and side effects. This model could set a new standard for chronic disease management, emphasizing integrated and accessible care beyond just prescription fulfillment.
What's Next?
The collaboration between Counsel Health and Eli Lilly through the LillyDirect platform is expected to expand access to this AI-native weight management program across the U.S. As the percentage of U.S. adults taking GLP-1 medications for weight loss has risen significantly, from 3% in 2024 to 11% in 2026, the demand for comprehensive care models that prioritize continuity and quality will likely continue to grow. Counsel Health's approach, which includes proactive AI check-ins and immediate physician access, could influence how other healthcare providers and pharmaceutical companies structure their support programs for chronic conditions. The success of this model in improving patient adherence and outcomes will be closely watched, potentially leading to broader adoption of AI-driven personalized care in other therapeutic areas.
Beyond the Headlines
This development highlights a broader trend in healthcare: the increasing integration of artificial intelligence to personalize and democratize access to medical care. The ethical implications of AI in healthcare, particularly concerning patient data privacy and the balance between AI-driven recommendations and human physician oversight, will become more prominent. While AI offers efficiency and accessibility, ensuring that the technology complements rather than replaces the human element of care is crucial. The model's focus on continuous support and personalized care also underscores a shift from episodic treatment to long-term health management, potentially reducing the burden on traditional healthcare infrastructure and improving overall public health outcomes by addressing chronic conditions more effectively. This could also lead to new regulatory frameworks for AI in medical practice.
